Evaluation of Risk of hEpatocellular Carcinoma

Recruiting N/A Interventional Study
NASH HCC Genetic Predisposition
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
45 – 75
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
500 (estimated)
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Hepatocellular carcinoma (HCC) is the fifth most common solid cancer and the second cause of cancer-related mortality worldwide. Nonalcoholic fatty liver disease (NAFLD), that is hepatic accumulation of fat in excess of 5% not explained by at risk alcohol intake, is projected to become the leading cause of HCC in Western countries within 2025.NAFLD is most frequently caused by insulin resistance d…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis of NAFLD or cryptogenic liver disease, allowing a more liberal alcohol intake limit (\<60/40 g/day in M/F), so as to also include subjects with a moderate alcoholic component of liver disease, an important factor given the high epidemiological burden of this group * …
Contacts

Luca Vittorio Carlo Valenti

02 5503 6595

luca.valenti@policlinico.mi.it

CONTACT